Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2024 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Short term Debt data on record, last reported at $8.4 million in Q2 2025.

  • For Q2 2025, Short term Debt rose 184.58% year-over-year to $8.4 million; the TTM value through Jun 2025 reached $8.4 million, up 184.58%, while the annual FY2014 figure was $1.0 million, N/A changed from the prior year.
  • Short term Debt reached $8.4 million in Q2 2025 per VRDN's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $8.4 million in Q2 2025 and bottomed at $3.0 million in Q2 2024.